BioSpace News Archive

Sonnet BioTherapeutics Holdings, Inc., announced today that a Phase 1b/2a clinical trial of SON-1010 (IL12-FHAB) in combination with Roche’s anti-PD-L1 checkpoint inhibitor, atezolizumab (Tecentriq®), has been approved to begin in Australia.

Sequantrix GmbH, a biotech start-up on a mission to unlock novel antifibrotic therapies, announced the launch of its operations.

Axena Health, Inc., a FemTech medical device company focused on scalable treatments for female pelvic health, introduced the Leva® Pelvic Health System for the first-line treatment of chronic fecal incontinence, also called accidental bowel leakage, in women.

Twist Bioscience Corporation today announced the appointment of Chet Gandhi as chief information officer.

PaxMedica, Inc. announced that its CEO, Howard Weisman, participated in a webcast on Saturday, June 17th, hosted by The BRAIN Foundation.

Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (NASDAQ: CTXR) today announced results from the Company’s Phase 2b clinical study of Halo-Lido (CITI-002), a topical formulation for the relief of hemorrhoid symptoms.

Owlet (NYSE: OWLT, “the Company”), the pioneer of smart baby monitoring, announces clearance from the U.S. Food and Drug Administration (“FDA”) of BabySat™ , the first medical pulse-oximetry device featuring its advanced, wire-free sock design.

Veracyte, Inc. (Nasdaq: VCYT) announced that new data presented at ENDO 2023, the annual meeting of The Endocrine Society, suggest the company’s Afirma molecular testing and whole-transcriptome capabilities can provide novel insights that may advance the scientific understanding of thyroid nodule biology.

20/20 Imaging, a division of Konica Minolta Healthcare Americas, Inc. and a leader in veterinary imaging solutions, announced a distribution agreement with Medovate Ltd., a medical device development company based in Cambridge, UK, to bring the pioneering SAFIRA® system for regional anesthesia to the US veterinary market.

ADvantage Therapeutics, Inc. today announced that regulatory authorities in Poland, Bulgaria, and Slovakia have approved its Clinical Trial Application (CTA) to conduct a clinical trial on its lead candidate, AD04™ for the treatment of mild Alzheimer’s disease (AD) in each respective country.